For the year ending 2025-12-31, IMCR had -$14,681K decrease in cash & cash equivalents over the period. -$15,052K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue | 400,016 |
| Cost of revenue from sale of therapies | 5,087 |
| PRAMEPrograms | 82,594 |
| Tebentafusp Programs | 40,824 |
| Infectious Disease Programs | 6,450 |
| Other Clinical And Pre Clinical Costs | 59,716 |
| R&d expenses-External RD | 189,584 |
| R&d expenses-Salaries And Other Employee Related Cost | 49,898 |
| Sg&a-Salaries And Other Employee Related Cost | 48,657 |
| Sg&a-Other Selling General And Administrative Expenses | 87,836 |
| Other segment expense, net | 54,468 |
| Net loss | -35,514 |
| Share-based compensation expense | 37,698 |
| Depreciation | 3,266 |
| Unrealized foreign exchange losses (gains) | 6,385 |
| Unrealized gains on marketable securities | 19,728 |
| Loss on loan extinguishment | 0 |
| Non-cash lease expense | 2,348 |
| Deferred income taxes | 14,790 |
| Other | -2,113 |
| Increase in accounts receivable | 7,336 |
| (increase) decrease in prepayments and other current assets | 6,740 |
| (decrease) increase in accounts payable | -2,456 |
| Increase in accrued expenses | 15,889 |
| Decrease in deferred revenue | -387 |
| Decrease in operating lease liabilities | -2,093 |
| Increase in other operating assets | 6,177 |
| Decrease in other operating liabilities | 0 |
| Net cash (used in) provided by operating activities | -10,712 |
| Proceeds from sale of property, plant and equipment | 0 |
| Proceeds from sale of marketable securities | 18,000 |
| Purchase of marketable securities | 30,000 |
| Purchase of property, plant and equipment | 4,340 |
| Net cash used in investing activities | -16,340 |
| Proceeds from issue of ordinary shares, net | 0 |
| Exercise of share options | 12,371 |
| Loan repayments | 0 |
| Debt prepayments and extinguishments | 0 |
| Non-current interest-bearing loan received | 0 |
| Debt issuance payments | 0 |
| Net cash provided by financing activities | 12,371 |
| (decrease) increase in net cash and cash equivalents | -14,681 |
| Net foreign exchange difference on cash held | 26,659 |
| Cash and cash equivalents at beginning of year | 455,731 |
| Cash and cash equivalents at end of year | 467,709 |
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)